Blue Cap continues to deliver with c 10% organic sales growth in H118 and confirmation that the recent, potentially transformative investment (Knauer) is well in hand. The shortfall in profit (EBIT down by 25%) was, as expected, rather a matter of timing as the impact of the disposal of a significant contributor to H117 (Biolink) was compounded by the initial inclusion of underperforming Knauer. Consensus forecasts for this year and next are therefore maintained, given renewed evidence of pro
14 Sep 2018
Blue Cap - Well on track
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Blue Cap - Well on track
Blue Cap AG (B7E:ETR) | 0 0 1.5% | Mkt Cap: 66.1m
- Published:
14 Sep 2018 -
Author:
Richard Finch -
Pages:
3
Blue Cap continues to deliver with c 10% organic sales growth in H118 and confirmation that the recent, potentially transformative investment (Knauer) is well in hand. The shortfall in profit (EBIT down by 25%) was, as expected, rather a matter of timing as the impact of the disposal of a significant contributor to H117 (Biolink) was compounded by the initial inclusion of underperforming Knauer. Consensus forecasts for this year and next are therefore maintained, given renewed evidence of pro